Exelixis (NASDAQ:EXEL – Get Rating) had its target price lowered by equities researchers at Piper Sandler from $34.00 to $30.00 in a report issued on Monday, The Fly reports. Piper Sandler’s price objective would indicate a potential upside of 45.70% from the stock’s previous close. A number of other analysts have also commented on EXEL. […]
Louisiana State Employees Retirement System boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 1.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,400 shares of the biotechnology company’s stock after purchasing an additional 1,000 […]